Key Developments in Obesity Medicine in 2023: An Expert Discussion

"What are the most important pharmaceutical and/or research developments in weight management and obesity medicine in 2023?"

Was a question Patient Care Online asked Angela Fitch, MD, president of the Obesity Medicine Association, in a recent interview. In the video below, Dr Fitch discusses advancements in the nutrient-stimulated hormone category of drug therapy for obesity; the release of tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone mimetic; and more.

Dr Fitch is also the founder and chief medical officer at knownwell and the former co-director of the Massachusetts General Hospital Weight Center and faculty at Harvard Medical School.